NASDAQ:HOTH Hoth Therapeutics (HOTH) Stock Price, News & Analysis $0.86 +0.01 (+1.18%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Hoth Therapeutics Stock (NASDAQ:HOTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hoth Therapeutics alerts:Sign Up Key Stats Today's Range$0.86▼$0.9150-Day Range$0.69▼$1.2652-Week Range$0.58▼$1.73Volume131,039 shsAverage Volume1.45 million shsMarket Capitalization$5.94 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingBuy Company OverviewHoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Read More… Nvidia warning urgent (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Hoth Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks66th Percentile Overall ScoreHOTH MarketRank™: Hoth Therapeutics scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingHoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHoth Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Hoth Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Hoth Therapeutics are expected to grow in the coming year, from ($1.18) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hoth Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hoth Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHoth Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Hoth Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.58% of the float of Hoth Therapeutics has been sold short.Short Interest Ratio / Days to CoverHoth Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHoth Therapeutics does not currently pay a dividend.Dividend GrowthHoth Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.58% of the float of Hoth Therapeutics has been sold short.Short Interest Ratio / Days to CoverHoth Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media1.6 / 5News Sentiment-0.16 News SentimentHoth Therapeutics has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Hoth Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for HOTH on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows1 people have added Hoth Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Hoth Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $16,750.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.56% of the stock of Hoth Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.08% of the stock of Hoth Therapeutics is held by institutions.Read more about Hoth Therapeutics' insider trading history. Receive HOTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HOTH Stock News HeadlinesHoth Therapeutics Up 34% on Favorable Early Data for Preclinical Study of Cancer DrugOctober 30 at 1:20 AM | marketwatch.comHoth Therapeutics: Treatment ‘successfully’ stabilized tumor growth in studyOctober 30 at 1:20 AM | markets.businessinsider.comCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!November 2, 2024 | Crypto 101 Media (Ad)Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment StudyOctober 29, 2024 | prnewswire.comHoth Therapeutics, Inc.October 17, 2024 | cnn.comHoth Shares Rise After Alzheimer's Treatment Gets PatentOctober 15, 2024 | marketwatch.comHoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now UnderwayOctober 15, 2024 | prnewswire.comHoth Therapeutics Reports Encouraging Pre-clinical Data For Its Alzheimer's Drug; Stock UpSeptember 17, 2024 | markets.businessinsider.comSee More Headlines HOTH Stock Analysis - Frequently Asked Questions How have HOTH shares performed this year? Hoth Therapeutics' stock was trading at $1.44 at the start of the year. Since then, HOTH shares have decreased by 40.3% and is now trading at $0.86. View the best growth stocks for 2024 here. How were Hoth Therapeutics' earnings last quarter? Hoth Therapeutics, Inc. (NASDAQ:HOTH) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.15. When did Hoth Therapeutics' stock split? Hoth Therapeutics shares reverse split on the morning of Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Hoth Therapeutics IPO? Hoth Therapeutics (HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO. How do I buy shares of Hoth Therapeutics? Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Hoth Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hoth Therapeutics investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Meta Platforms (META), NVIDIA (NVDA) and Zomedica (ZOM). Company Calendar Last Earnings8/09/2024Today11/02/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HOTH CUSIPN/A CIK1711786 Webwww.hoththerapeutics.com Phone(646) 756-2997FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+307.0%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.78% Return on Assets-74.38% Debt Debt-to-Equity RatioN/A Current Ratio14.62 Quick Ratio14.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.03 per share Price / Book0.42Miscellaneous Outstanding Shares6,904,000Free Float6,175,000Market Cap$5.94 million OptionableNot Optionable Beta0.84 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:HOTH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.